National Guizhou Joint Engineering Laboratory for Cell Engineering and Biomedicine Technique, Center for Tissue Engineering and Stem Cell Research, Guizhou Province Key Laboratory of Regenerative Medicine; Department of Pharmacology, School of Basic Medicine, Guizhou Medical University, Guiyang, China.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4537-4538. doi: 10.26355/eurrev_202004_21037.
At present, SARS-Cov-2 is spread all over the world, becoming a serious threat to people's health. SARS-Cov-2 has a strong infection, and the mortality rate of severe patients after infection is high, but there is no effective treatment. Mesenchymal stem cells (MSCs) have anti-inflammatory and immunomodulatory functions, which can reduce the occurrence of cytokine storm syndrome and acute respiratory distress syndrome. At the same time, MSCs can reduce the level of pulmonary fibrosis and enhance tissue injury repair. In this short report, combined with the progress of preclinical and clinical research, we comment the efficacy of MSCs in the treatment of COVID-19.
目前，SARS-CoV-2 在全球范围内传播，严重威胁着人们的健康。SARS-CoV-2 具有很强的感染力，感染后的重症患者死亡率较高，但目前尚无有效的治疗方法。间充质干细胞（MSCs）具有抗炎和免疫调节功能，可减少细胞因子风暴综合征和急性呼吸窘迫综合征的发生。同时，MSCs 可以降低肺纤维化水平，增强组织损伤修复。在这份简短的报告中，我们结合临床前和临床研究的进展，对 MSCs 治疗 COVID-19 的疗效进行了评论。
